Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib + Conditioning + Allo-SCT for CML
NCT00499889Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2003
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2003; status: terminated.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00499889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499889.